YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Population Pharmacokinetic Modeling of Vancomycin in Patients with Cancer

암환자에게 반코마이신의 집단약물동태학 모델연구

  • Published : 1999.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

The purpose of this study was to determine pharmacokinetic parameters of vancomycin using peak and trough plasma level (PTL) and Bayesian analysis in 20 Korean normal volunteers, 16 gastric cancer and 12 lymphoma patients and also using the compartment model dependent (nonlinear least squares regression: NLSR) and compartment model independent (Lagrange) analysis in 10 ovarian cancer patients. Nonparametric expected maximum (NPEM) algorithm for calculation of the population pharmacokinetic parameters was used, and these parameters were applied for clinical pharmacokinetic parameters by Bayesian analysis. Vancomycin was administered as dose of 1.0 g every 12 hrs for 3 days by IV infusion over 60 minutes in normal volunteers, gastric cancer and lymphoma patients. Population pharmacokinetic parameters, K and Vd in gastric cancer and lymphoma patients using NPEM algorithm were $0.158{\pm}0.014{\;}hr^{-1},{\;}0.630{\pm}0.043{\;}L/kg{\;}and{\;}0.131{\pm}0.0261{\;}hr^{-1},{\;}0.631{\pm}0.089{\;}L/kg$ respectively. The K and Vd in gastric cancer and lymphoma patients using Bayesian analysis were $0.151{\pm}0.027,{\;}0.126{\pm}0.056{\;}hr^{-1}{\;}and{\;}0.62{\pm}0.105,{\;}0.63{\pm}0.095{\;}L/kg$. The K and Vd in ovarian cancer patient using the NLSR and Lagrange analysis were $0.109{\pm}0.008,{\;}0.126{\pm}0.012{\;}hr^{-1}{\;}and{\;} 0.76{\pm}0.08,{\;}0.69{\pm}0.19{\;}L/kg$, respectively. It is necessary for effective dosage regimen of vancomycin in cancer patients to use these population parameters.

Keywords

References

  1. Rev. Infect. Dis. v.3 The Antibacterial action of vancomycin Watanakunakorn, C.
  2. J. Am. Chem. Soc. v.105 Vancomycin structure and trasformation Harris, C. M.;Kopecka, H.
  3. J. Antimacrob. Chemother v.14 Vancomycin therapy of severe staphylococcal infections Kirby, W. M. M.
  4. J. Infect. Dis. v.147 Vancomycin treatment of bacteremia caused by oxacillin resistant staphylococcus aureus : comparison with β-lactam antibiotics treatment of bacteremia caused by oxocillin-sensitive staphylococcus aureus Craven, D. E.
  5. J. Kor. Soc. Hosp. Pharm. v.4 Theophylline clearance of Korean population in comparison with American Kim, J. K.;Yoo, D. S.;Shin, H. T.;Kim, N. D.;Kim, J. K.;Kim, G. Y.;Kim, Y. K.
  6. Clin. Pharmacol. Ther. v.37 A Bayesian method of aminoglycoside dosing Burton, M. E.;Brater, D. C.;Chen, P. S.
  7. Drug. Intell. Clin. Pharm. v.22 Validation of use of Bayesian analysis in the optimization of gentamicin therpy from the commencement of dosing Chrystn, H.
  8. Antimicrob. Agents Chemother. v.34 Application of a Bayesian method to monitor and adjust vancomycin dosage regimens Hurst, A.;Yoshinaga, M.;Mitani, G.;Foo, K.;Jelliffe, R.;Harrison, E.
  9. Clin. Pharmacokinet. v.21 Individualizing gentamicin dosage regimens. A comparative review of selected methods. Data fitting methods and monitoring strategies Jelliffe, R. W.;Iglesias, T.;Hurst, A. K.
  10. Clin. Pharmacokinet v.22 Bayesian parameter estimation and population pharmacokinetics Thomson, A. H.;Whiting, B.
  11. J. Pharmacokinet. Biopharm. v.4 Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions : Gentamicin in burn patients Sawchuk, R. J.;Zaske, D. E.
  12. variability if drug therapy: description, estimation, and control Estimating interindividual pharmacokinetic variability Steimer, J. L.;Mallet, A.;Mentre, F.
  13. statistical methodology in the pharmaceutical sciences Population models Racine-Poon, A.;Smith, A. F. M.
  14. Drug Metab. Rev. v.16 Population pharmacokinc data and parameter estimation based on their first two statistical moments Beal, S.
  15. Technical report of Divistion of Clinical Pharmacology Asymptotic properties of optimization estimates for the independent net identically distributed case with application to extended least-squares estimate Beal, S.
  16. Techinical report of the division of Clinical Pharmaology NONMEM users guide-part 1: users basic guide Beal, S.;Sheiner, L.
  17. Biometrika v.73 A maximum linkelihood estimation method for random coefficient regression models Mallet, A.
  18. J. Pharmacokinet. Biopharm. v.16 Nonparametric maxmum likelihood estimation for population pharmacokinetics, with application to cyclosporine Mallet, A.;Mentre, F.;Steimer, J. L.;Lookiec, F.
  19. Clin. Pharmacokinet. v.23 Population pharmacokinetics of gentamicin: use of the nonparemetric expectation miximisation (NPEM) algorithm Kisor, D. F.;Watling, S. M.;Zarowitz, B. J.;Jelliffe, R. W.
  20. Applied Mathematics and Computations v.45 Nonparametric EM algorithms for estimating prior distributions Schumitzky, A.
  21. Clin. Pharmacol. and Ther. v.50 Gentamicin population pharmacokinetic models for low birth weight infants; using a new non-parametric algorithm Dodge, W. F.;Jellife, R. W.;Richardson, C. J.;McCleery, R. A.;Hokanson, J. A.
  22. Ther. Drug Monit. v.14 Pharmacokinetic population parameters for aminoglycosides in cholecystitis patients Gill, M. A.;Okamoto, M. P.;Nakahiro, R. K.;Chin, A.;Inagaki, K.;Sclar, D.
  23. Antimicrob. Agents Chemother v.37 Comparison of population pharmacokinetic models for gentamicin in spinal cord-injured and able-bodies patients Gilman, T. M.;Brunnemann, S. R.;Segal, J. L.
  24. User manual for the nonparametric EM program for population pharmacokinetic modeling version 1 Jelliffe, R. W.;Schumitzky, A.
  25. Kor. J. Clin. Pharm. v.2 Clinical pharmacokinetics of gentamicin in appendicitis patients Choi, J. S.;Burm, J. P.;Lee, J. H.
  26. Yakhak Hoeji v.40 Clinical pharmacokinetics of gentamicin in gastrointestinal surgical patients Choi, J. S.;Moon, H. S.;CHoi, I.;Burm, J. P.
  27. Antimicrob. Agents Chemother v.38 Comparison of aminoglycoside pharmacokinetics in asian, hispanic, and caucasian patients by using population pharmacokinetic methods Jhee, S. S.;Burm, J. P.;Gill, M. A.
  28. Yakhak Hoeji v.39 Population pharmacokinetics for gentamicin in American and Korean-American appendictis patients using nonparametric expected maximum algorithm Burm, J. P.;Choi, J. S.;Jhee, S.;Gill, M. A.
  29. Ther. Drug Monitor. v.5 Automated fluorescence polarization immunoassay for monitoring vancomycin Schwenzer, K. S.
  30. Ann. Intern. Med. v.94 Vancomycin therapy in patients with impsired renal function Moellering, R. C.
  31. Clin. Pharmacol. Ther. v.37 Vancomycin multi-dose kinetics in critically ill patients Narang, P. K.
  32. Clin. Pharmacol. Ther. v.50 Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance Marcias, W. L.
  33. Clin. Pharmacol. Ther. v.44 Altered vancomycin dose vs. serum concentration relationship in burn patients Garrdlts, J. C.;Peterie, J. D.
  34. Clin. Pharmacol. Ther. v.39 Vancomycin elimination in patients with burn injury Brater, D. C.
  35. J. Antimicrob. Chemother. v.14(supply) Vancomycin pharmacokinetics in critically ill patients Guraud, J. J.
  36. Clin. Pharmacokinet. v.21 Individualizing gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring stategies Jelliffe, R. W.;Iglesiias, T.;Hurst, A.;Foo, K.;Rodriguez, J.
  37. Clin. Pharmacokinet. v.20 An updated comparison of drug dosing methods. Part Ⅲ: aminoglycoside antibiotics Erdmann, S. M.;Rodvold, K.;Pryka, R. D.
  38. Clin. Pharmacol. Ther. v.37 A Bayesian feedback method for aminoglcoside dosing Burton, M. E.;Brather, D. C.;Chen, P. S.;Say, R. B.;Hubber, J. J.;Vasko, M. R.
  39. Clin. Pharm. v.6 Comparison of four methods for predicting serum gentamicin concentrations in surgical patients with perforated or gangrenous appendicitis Hurst, A. K.;Iseri, K. T.;Gill, M. A.;Nofuchi, J. G.;Gilman, T. M.;Jelliffe, R. W.
  40. Clin. Pharm. v.12 Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies Fernandez D. G.